Theorem Clinical Research

Drug Sponsors

uniQure acquires cardiology gene therapy company InoCard

Wednesday, August 13, 2014 01:11 PM

uniQure, an Amsterdam, Netherlands-based provider of human gene therapy, has acquired InoCard, a Germany-based early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

More... »


Cellular Biomedicine Group acquires Agreen Biotech

Wednesday, August 13, 2014 01:01 PM

Cellular Biomedicine Group, a California-based developer of new treatments for degenerative and cancerous diseases, has acquired China-based Agreen Biotech and its founder’s U.S. patent for $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units.

More... »


Oncothyreon acquires Alpine Biosciences

Wednesday, August 13, 2014 12:59 PM

Oncothyreon, a Washington-based biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, has acquired Alpine Biosciences, a Seattle, Wash.-based privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules. 

More... »

Galenica lays foundation for two listed, independent companies

Wednesday, August 13, 2014 12:57 PM

The Galenica Group, a Switzerland-based healthcare group that develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks, plans to separate into two independent companies.

More... »

Marathon Pharmaceuticals opens bioscience center in Chicago

Thursday, August 7, 2014 09:00 AM

Marathon Pharmaceuticals has opened the Marathon Bioscience Center in Chicago. The facility houses the company’s research, clinical and regulatory staff, who develop and register new treatments for rare diseases.

More... »

Alvogen acquires Korean Dream Pharma for $187 million

Thursday, August 7, 2014 08:00 AM

Alvogen, an international, privately owned pharmaceuticals company, has acquired Dream Pharma of South Korea for $187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, the combination will create one of the largest generic pharmaceutical companies in South Korea.

More... »

Telik completes merger with MabVax Therapeutics

Tuesday, August 5, 2014 10:00 AM

MabVax Therapeutics, a privately held cancer immunotherapy company, and Telik, a clinical stage oncology drug development company, have merged. MabVax became a wholly owned subsidiary of Telik effective July 8, following Telik stockholder approval at Telik's annual meeting of stockholders July 7.

More... »

Roche to acquire Santaris Pharma for $450M

Monday, August 4, 2014 02:14 PM

Roche has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark. Santaris Pharma has pioneered its proprietary Locked Nucleic Acid (LNA) platform that has contributed to an emerging era of RNA-targeting therapeutics. This new class of medicines has the potential to address difficult to treat diseases in a range of therapeutic areas.

More... »

Pfizer, Roche join ADDPLAN DF Consortium

Monday, August 4, 2014 02:12 PM

Pfizer and Roche have joined the ADDPLAN DF Consortium. The consortium was founded in 2013 by Novartis, Janssen PharmaceuticalsEli Lilly and Aptiv Solutions, an Icon company, to lead the design and implementation of adaptive trials. The goal of the ADDPLAN DF Consortium is to develop methodologies and execution technologies that improve dose-selection, which remains a major barrier to resolving high failure rates in phase III trials.

More... »

Allergan files federal lawsuit against Valeant, Pershing Square

Monday, August 4, 2014 02:10 PM

Allergan has filed a lawsuit against Valeant Pharmaceuticals InternationalPershing Square Capital Management and its principal, William A. Ackman, alleging that Valeant, Pershing Square and Ackman violated federal securities laws prohibiting insider trading, engaged in other fraudulent practices and failed to disclose legally required information.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 2

Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity

FDA action plan seeks to close gap in women and minority patient representation in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs